Article metrics

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

 

Online download statistics by month:

Online download statistics by month: September 2019 to September 2024

AbstractFullPdf
Sep 201910171016453
Oct 2019386338431796
Nov 201919871957872
Dec 201916911660667
Jan 202017071674664
Feb 202013051277531
Mar 202010991066457
Apr 2020795774348
May 2020870860439
Jun 2020858835399
Jul 2020810768462
Aug 2020732697274
Sep 2020811785343
Oct 2020790772406
Nov 2020712689378
Dec 2020606570275
Jan 2021606571272
Feb 2021668620281
Mar 2021568546273
Apr 2021568535277
May 2021710692230
Jun 2021513497202
Jul 2021446426178
Aug 2021536513172
Sep 2021459428195
Oct 2021472450258
Nov 2021488465220
Dec 2021354338126
Jan 2022392378147
Feb 2022384364153
Mar 2022654626202
Apr 2022591563171
May 2022544542205
Jun 2022477470172
Jul 2022347343118
Aug 2022395377119
Sep 2022425416150
Oct 2022406392156
Nov 2022427411152
Dec 202236433992
Jan 202339437291
Feb 2023382354202
Mar 2023455427151
Apr 2023306283118
May 2023382358172
Jun 202330527488
Jul 202328526496
Aug 202325522898
Sep 2023266244101
Oct 202330729094
Nov 2023308294118
Dec 202332029595
Jan 2024262228140
Feb 2024290257112
Mar 2024370349154
Apr 2024454433179
May 2024300274104
Jun 2024373356110
Jul 2024338327136
Aug 2024341324111
Sep 2024372359129
Total385123713515884